ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy
- Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO (United States)
- Department of Pharmacology, University of Colorado Health Sciences Center, Aurora, CO (United States)
- Dipartimento di Oncologia, dei Trapianti e delle Nuove Technologie in Medicina, Universita di Pisa, Pisa (Italy)
- Department of Molecular and Clinical Endocrinology, Universita degli Studi di Napoli Federico II, Naples (Italy)
- AstraZeneca, Wilmington, DE (United States)
Radiation enhances both epithelial growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) expression, which are a part of key pathways for tumor progression. Some tumors may not respond well to EGFR inhibitors alone or may develop resistance to EGFR inhibitors. Therefore, drug therapy targeted to VEGF receptors and EGFRs, when combined with radiotherapy (RT), may improve tumor control and provide wider applicability. This article focuses on ZD6474, an inhibitor of EGFR and VEGF receptor signaling in combination with RT. We discuss preclinical and clinical studies with RT and inhibitors of VEGF or EGFR signaling first. We then address issues associated with ZD6474 pharmacokinetic dosing, and scheduling when combined with RT. We also discuss ZD6474 in the context of anti-EGFR therapy resistance. Dual inhibition of EGFR and VEGF receptor signaling pathways shows promise in enhancing RT efficacy.
- OSTI ID:
- 20788263
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 64; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells